Practice
Featured experience
Cerebras Systems $6.4 billion IPO
We advised the underwriters on the IPO
Alphabet $20 billion notes offering
We advised the global coordinators and book-running managers on the offering
Arxis $1.3 billion IPO
We advised Arxis on its IPO
Novartis $11 billion notes offering
We advised Novartis on the investment-grade debt offering
British American Tobacco $750 million notes offering
The investment-grade notes are due 2033
Grayscale CoinDesk Crypto 5 ETF approved as first U.S. multi-asset crypto ETF
We advised Grayscale on securing SEC approval for the NYSE Arca listing
Applied Materials $1 billion senior notes offering
The investment-grade notes are due 2031 and 2036
GenFleet Therapeutics HK$1.82 billion IPO
We advised GenFleet on its IPO and HKEX listing
Baldwin Group $1.006 billion credit facilities financing
We advised the borrower on the refinancing and amendment
Oscar Health $410 million convertible senior subordinated notes and capped call transactions
The 2.25% convertible notes are due 2030
Norwegian Cruise Line Holdings comprehensive refinancing transactions
The transactions included new debt, exchangeable debt, registered direct equity offerings and concurrent tender offers
Bombardier $250 million senior notes offering
The investment-grade senior notes are due 2033
Natura sale of Avon International to Regent
We are advising Natura on the sale
Century Communities $500 million senior notes offering and concurrent redemption
The high-yield notes are due 2033